Navigation Links
American Who Exposed Air Passengers to Drug Resistant TB Quarantined

ws the bacteria to overcome the patient's immune defenses more quickly. About two-thirds of those infected with XDR-TB die, the World Health Organization said in March. In February, the Geneva- based agency asked donor countries and organizations to give $650 million to improve diagnosis and treatment of the disease.

``They'll probably need a lot more than that,'' said Tawanda Gumbo, a TB specialist at the University of Texas Southwestern Medical Center in Dallas who has treated patients with resistant strains in the U.S. and Zimbabwe. ``This is a major problem and we've been losing drugs to treat it one by one.''

Gerberding said the CDC is recommending that people who sat near the man on the two transatlantic flights - beside or two rows in front and two rows behind - be tested for tuberculosis. "We are considering not only his own ability to transmit but also the seriousness of this organism and the chance that some passenger on the plane could be one that was at a special risk for serious tuberculosis on the basis of their own personal medical history," she said.

Dr. Michael Gardam, a tuberculosis expert in Toronto, said people who sat near the man on those two flights face months of testing and uncertainty. "That's the real . . . tough story here, is that most of these people are not going to have been infected by this fellow, but it might be hard to know that," said Gardam, head of infection control at University Health Network, a consortium of three large Toronto teaching hospitals.

"It's going to be very anxiety provoking for the next two years." ``The risk of transmission may be on the low side, but we know it isn't zero,'' Gerberding said. "Anybody who comes into contact with XDR-TB could become infected." The man, a Georgia resident, left Atlanta on May 12 on Air France flight 385, arriving in Paris on May 13.

Gerberding said he had been advised by public health authorities in Georg
'"/>




Page: 1 2 3

Related medicine news :

1. Abstain from sex- the latest mantra of American teens
2. Clintons new problem - Is the outgoing American president suffering from skin cancer?
3. FDA attacks American Red Cross for blood violations
4. Poll Finds Many Americans Misinformed About Cancer
5. Poll Finds Many Americans Misinformed About Cancer
6. Hypertension Drug of Choice for African Americans
7. American scientists alter gene makeup of babies
8. 38 million Americans including 14 million children left to combat hunger
9. Americans Consume Far Too Much Salt and Sodium
10. Americans Growing Out Of Shape
11. Rise in Stress among Americans
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: American Who Exposed Air Passengers Drug Resistant Quarantined

(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... The condition ... among both men and women often causing pain and discomfort. Those who spend a ... circulatory problem, and Northeast Houston Vein Center is doing what it can to create ...
(Date:8/1/2015)... ... 01, 2015 , ... On Tuesday, July 28th, Symantec released a security industry ... been behind the attack on Anthem Inc. which resulted in one of the largest ... attacks and spear phishing campaigns. , For Joe Caruso, founder and CEO/CTO ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... magazine. What are the STASH awards? The Significant Technological Achievements in Secretive ... cannabis-cultivation community as well as tried-and-true products that have stood the test of ...
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... Ticket ... which is currently going on in Chicago at Grant Park. The festival will ... corner of North America to Chicago for the annual Lollapalooza. This unique and ...
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 , ... ... CoolSculpting , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator ... FDA in January 2014 for treating the outer thighs. The original applicator required ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... PARI,s Hydrate, a novel,medical humidifier, was awarded a ... 18, 2007. PARI Innovative Manufacturers, a leading,manufacturer of ... the way gases are heated and humidified with ... give clinicians greater control,of patient comfort. The ...
... local extinctions in a majority of species while enhancing ... the University of Illinois shows that parasites can play ... fragmented forests. This is the first study to look ... parasites on animals already stressed by disturbances to their ...
... Verathon Medical(R), the global,leader in the ... is pleased to announce that the European ... -- European Patent 1307131 B1 --,against a ... This,patent protects Verathon,s invention of its innovative, ...
... Public Schools in New York, New ... Jersey and Connecticut, ... rate monitors and fitness assessment technology, and a founding,member of the ... provide grant recipients in New York, New,Jersey and Connecticut with heart ...
... Community Urges SJHS to Agree to Fair Union Election ... and activist Ed Begley, Jr., will be among those ... St. Jude Medical,Center at a procession Saturday outside the ... workers seeking to form a union at SJHS hospitals ...
... Louis Sullivan, M.D., Former Secretary of HHS, Senator Norm ... Mark McClellan, M.D., Ph.D., and,members of the patient and ... the scientific evidence countering the United States Preventive, Services ... Screening, ARLINGTON, Va., Oct. 24 The Potomac,Institute ...
Cached Medicine News:Health News:PARI's Hydrate Wins Prestigious R&D 100 Award 2Health News:Parasites a key to the decline of red colobus monkeys in forest fragments 2Health News:Parasites a key to the decline of red colobus monkeys in forest fragments 3Health News:European Patent Office Upholds Verathon's IP Against Aircraft Medical Challenge 2Health News:Polar Joins Alliance to Combat Childhood Obesity 2Health News:Polar Joins Alliance to Combat Childhood Obesity 3Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 2Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 3Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 4Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 5
(Date:7/30/2015)... July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... valves and hemodynamic monitoring, today announced that Robert A. ... "Bob is an ardent champion for innovation in ... to have him on Edwards, board as we pursue our ... chairman and CEO.  "Bob has provided a valuable perspective to ...
(Date:7/30/2015)... July 30, 2015  Tandem Diabetes Care®, Inc. ... and manufacturer of the t:slim® and t:flex™ Insulin ... non-exclusive Development Agreements with Dexcom, Inc. to allow ... with the Dexcom G5 and G6 continuous glucose ... generation pump platform with Dexcom,s future CGM systems ...
(Date:7/30/2015)... THOUSAND OAKS, Calif., July 30, 2015  Amgen ... for the second quarter of 2015. Key results ... versus the second quarter of 2014 to $5,370 ... primarily by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... ANTIPOLIS, France, May 11, 2007 /PRNewswire-FirstCall/ --,NicOx S.A. ... phase 2a,study for NCX 1000, which is covered ... A preliminary analysis of 11 patients,from this proof-of-concept ... NCX 1000 but did not demonstrate the efficacy,required ...
... 2007--Sciele Pharma, Inc.,(NASDAQ:SCRX) today announced the successful completion ... formulation. The study,results showed that the new Sular ... new Sular formulation,utilizes SkyePharma's (LSE:SKP) patented Geomatrix technology,which ... Sular for each of its,current doses. , The ...
Cached Medicine Technology:NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 2Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 4
... standard in corneal diagnostics. Precise Display ... membrane, stroma, Bowman's membrane and epithelial ... Broad Applications in Surgery and Pathology. ... evaluation, endothelial cell analysis, haze detection, ...
... appearance of photo-aged skin, removes age spots ... and broken capillaries. This innovative new application ... pigmentary sun damage through a process called ... and the Nd:YAG Laser is optimized for ...
... affordable lenses available in a variety ... available in prescription powers for those ... "Plano" for those who don't. They ... technology. Incredibly comfortable, 10 fun, eye-catching ...
Each jet black lens features a mesmerizing thin white line that spirals toward the center of the pupil....
Medicine Products: